2025-04-24
Revolutionizing Gastric Cancer Treatment: Targeted Radiotherapy with Zolbetuximab and abinScience Support
Gastric cancer, the fifth most common cancer globally, poses significant treatment challenges due to late-stage diagnoses and chemotherapy resistance. A study from the Shanghai Institute of Applied Physics, published in Molecular Pharmaceutics, introduces a novel targeted radiotherapy approach using [131I]I-Zolbetuximab to treat CLDN18.2-positive gastric cancer. This radiolabeled antibody demonstrates high specificity, effective tumor suppression, and minimal toxicity in preclinical models, extending survival significantly. Compared to traditional treatments like chemotherapy and immunotherapy, this method offers precise tumor targeting. abinScience supports this innovation with research-grade biologics, advancing targeted therapy for gastric cancer.
